Skip to main content
. 2021 Dec 15;13(12):4481. doi: 10.3390/nu13124481

Table 4.

Exploratory outcomes at end of intervention and changes from baseline.

Placebo
(n = 28)
Change (95% CI) Placebo Synbiotics
(n = 28)
Change (95% CI)
Synbiotics
p-Value a
Echocardiographic characteristics
Global longitudinal strain (%)
(n = 52)
−17.2 ± 3.5 0.40 (−0.96–1.77) −17.6 ± 3.2 0.01 (−1.28–1.31) 0.98
Left ventricular mass index (g/m2)
(n = 55)
72.6 (63.2–88.0) −5.00 (−11.9–1.93) 81.0 (69.0–94.4) −6.40 (−15.9–3.11) 0.29
Ejection fraction (%) (n = 54) 58.0 (53.5–63.0) −2.86 (−5.82–0.11) 60.5 (57.0–64.0) −1.23 (−4.61–2.08) 0.25
Uremic toxins (n = 55)
Total indoxyl sulfate (µmol/L) 13.0 (8.0–18.5) −3.07 (−9.14–2.99) 12.0 (6.7–28.0) 1.50 (−3.25–6.26) 0.96
Total p-cresyl sulfate (µmol/L) 64.5 (24.0–135.0) −17.2 (−49.8–15.3) 69.0 (30.0–179.0) 28.8 (−6.32–64.0) 0.15
Free indoxyl sulfate (µmol/L) 0.8 (0.4–1.2) −0.09 (−0.34–0.17) 0.8 (0.5–1.2) 0.10 (−0.14–0.34) 0.25
Free p-cresyl sulfate (µmol/L) 2.6 (0.9–5.1) −0.17 (−1.18–0.84) 2.7 (1.4–5.8) 0.98 (0.17–1.79) 0.08
Blood pressure
Systolic BP (mmHg) 142 ± 17 4.11 (−3.21–11.4) 142 ± 19 1.79 (−6.95–10.5) 0.89
Diastolic BP (mmHg) 81 ± 9 2.39 (−0.81–5.59) 77 ± 8 1.18 (−2.36–4.72) 0.16
eGFR (mL/min/1.73 m2) 38.5 (29.5–49.0) 2.61 (−0.41–5.63) 29.0 (20.0–36.0) −3.14 (−6.23–−0.06) <0.01
Creatinine (µmol/L) 149 (126–182) −9.79 (−21.7–2.09) 177 (156–249) 20.8 (2.97–38.5) <0.01
Cholesterol (mmol/L) 4.6 (3.6–5.0) −0.07 (−0.37–0.23) 4.1 (3.4–5.0) −0.07 (−0.34–0.20) 0.59
HDL cholesterol (mmol/L) (n = 55) 1.1 (0.9–1.2) −0.02 (−0.07–0.04) 1.1 (0.9–1.5) 0.05 (−0.23–0.32) 0.57
LDL cholesterol (mmol/L) (n = 55) 2.4 (1.7–2.7) −0.26 (−0.51–−0.01) 2.0 (1.7–2.7) −0.09 (−0.25–0.08) 0.84
Triglycerides (mmol/L) 1.9 (1.4–2.6) 0.18 (−0.11–0.47) 1.3 (0.9–2.1) −0.03 (−0.31–0.25) 0.14

Data are presented as means ± SD, median (25th–75th percentiles), or numbers (%); CI = confidence interval. a p-values calculated for the group effect using analysis of covariance.